Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference

AUSTIN, Texas — May 19, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below:

**William Blair Growth Stock Conference**

Date: Tuesday, June 1 – Thursday, June 3, 2021  
Presentation: Thursday, June 3 at 9:00 am ET  
Webcast: [https://wsw.com/webcast/blair58/awh/1770080](https://wsw.com/webcast/blair58/awh/1770080)

**About Aspira Women’s Health Inc.**

Aspira Women’s Health Inc. (Nasdaq: AWH) (formerly known as Vermillion, Inc.) is transforming women’s health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Women’s Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1® plus includes our FDA-cleared products, OVA1® and OVERA®, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiX™ testing offers both targeted and more comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Women’s Health is delivering a portfolio of pelvic mass products over a patient’s lifetime with our cutting-edge research. The next generation of products in development are OVANEX™ and EndoCheck™. Visit our website for more information at [www.aspirawh.com](http://www.aspirawh.com).

**Investor Relations Contact:**  
Ashley R. Robinson  
LifeSci Advisors, LLC  
Tel: 617-430-7577  
arr@lifesciadvisors.com